Perspectives for a vaccine against hepatitis C virus

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 259-263

  Abrignani, Sergio ^a,b   Houghton, Michael ^a,b   Hsu, Henry H ^a,b  

^a CHIRON VACCINES   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

HCV vaccine; Protective immunity

Indexed keywords

CD4 ANTIGEN; DNA VACCINE; HEPATITIS VACCINE; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; CONFERENCE PAPER; ERADICATION THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; VACCINATION; VACCINE PRODUCTION; VIRUS DETECTION; VIRUS IMMUNITY;

EID: 0033406374     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80413-9     Document Type: Conference Paper

References (20)

1. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998: 47: 1-39.
2. World Health Organization. Wkly Epidemiol Rec 1997: 72: 6572.
3. Pagliaro L, Peri V, Linea C, Camma C, Giunta M, Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol 1999: 31: 28-44.
4. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sei USA 1996: 93: 1759-1763.
5. Pileri P, Uematsu Y, Campagnol! S, Galli G, Falugi F, Petracca R et al. Binding of hepatitis C virus to CD81. Science 1998: 282: 938-941.
6. Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998: 28: 1117-1120.
7. Knodell RG, Conrad ME, Ishak KG. Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis. Role of gamma-globulin prophylaxis in its prevention. Gastroenterology 1977: 72: 902-909.
8. Feray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynes M et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998: 128: 810-816.
9. Piazza M, Sagliocca L, Tosone G, Guadagnino V, Stazi MA, Orlando R et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997: 157: 1537-1544.
10. Yu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995: 345: 1173-1174.
11. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sei USA 1996: 93: 15394-15399.
12. Barnaba V, Franco A, Alberti A, Benvenuto R, Balsano F. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature 1990: 345: 258-260.
13. Botarelli P, Brunetto M, Minutello M, Calvo P, Unutmaz D, Weiner A et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993: 104: 580-587.
14. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga E, Santantonio T, Jung M et al. Possible mechanism involving Tlymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995: 346: 10061007.
15. Koziel MJ, Walker BD. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol 1997: 19: 69-83.
16. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999: 10: 439-449.
17. Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P et al. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Va24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol 1998: 28: 34483455.
18. Walker C. Comparative features of hepatitis C virus infection in humans and chimpanzees. Springer Semin Immunopathol 1997: 19: 85-98.
19. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sei USA 1994: 91: 1294-1298.
20. Inchauspe G, Major ME, Nakano I, Vivitski L, Maisonnas M, Trepo C. Immune responses against hepatitis C virus structural proteins following genetic immunisation. Dev Biol Stand 1998: 92: 163-168.